Skip to content

Genmab

US · GMAB #860 by market cap Listed 2019
50.60 -0.75 -1.46%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:56

About Genmab

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Founded
1998
CEO
Dr. Jan G. J. van de Winkel, PhD
Employees
2,819
Headquarters
Copenhagen, Central Denmark, Denmark
Fiscal year end
12-31
Website
genmab.com

Company profile

Exchange
US
Symbol
GMAB
Market-cap rank
#860
Listing date
2019-07-18
Market cap
31.20B
Float cap
29.01B
Shares out
616.59M
Float shares
573.24M

Sectors & themes

Browse all sectors & themes

Quote time 2026-11-20 19:56:12 · For reference only, not investment advice and not tailored to your situation.

Genmab discussion 0 comments

Add a comment